Biotech Values

[mcbio]

It will remain to be seen what GSK does with some of its partnered early assets. There might be some small partners feeling uneasy at the moment. Same is true for some of NVS small partners.

I guess as an FPRX long, I should consider the possibility that the partnership FPRX has with GSK for FP-1039, its FGF Ligand Trap, could be in trouble but I guess not if NVS has an interest? I'm happy to buy FPRX on any weakness on any negative development on this front though given that the reason for my investment in FPRX was primarily for their immuno oncology platform.

For NVS, I definitely now have some more pause on ARRY (was giving consideration to taking a position again at some point potentially). It certainly remains to be seen if NVS will favor Mekinist over MEK162.